moa semaglutide Ozempic vs. Wegovy vs. Mounjaro:

IP lifecycle management and formulary access strategy must be developed in parallel, not sequentially

KEY TAKEAWAYS PCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction 70 million women globally are affected during reproductive years, with 70% remaining undiagnosed The condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problems Treatment should focus on metabolic health rather than weight loss or ovarian interventions The name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver disease NOTABLE QUOTE "Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever

Diagnostic features: Biliary structures are usually glandular but may have solid or papillary areas, may be poor in or free of mucus, and mostly have a minimal connective tissue component

Part II: outcome analysis